261 related articles for article (PubMed ID: 26769126)
21. Circulating tumor cells in breast cancer--current status and perspectives.
Banys-Paluchowski M; Krawczyk N; Meier-Stiegen F; Fehm T
Crit Rev Oncol Hematol; 2016 Jan; 97():22-9. PubMed ID: 26563820
[TBL] [Abstract][Full Text] [Related]
22. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
[TBL] [Abstract][Full Text] [Related]
24. Advanced detection and measurement of cells on membrane from peripheral blood by laser scanning cytometry (LSC) in early stage breast cancer patients.
Sanislo L; Kuliffay P; Sedlak J; Kausitz J; Galbavy S
Bratisl Lek Listy; 2010; 111(1):13-9. PubMed ID: 20429306
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
26. Significance of immunoregulatory T cells in different stages of breast cancer patients.
Abo-Elenein A; Elgohary SE; Hashish A; El-Halaby E
Egypt J Immunol; 2008; 15(2):145-52. PubMed ID: 20306697
[TBL] [Abstract][Full Text] [Related]
27. Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy.
Sabbatini R; Federico M; Morselli M; Depenni R; Cagossi K; Luppi M; Torelli G; Silingardi V
J Clin Oncol; 2000 May; 18(9):1914-20. PubMed ID: 10784632
[TBL] [Abstract][Full Text] [Related]
28. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.
Zhang JL; Yao Q; Chen Y Wang JH; Wang H; Fan Q; Ling R; Yi J; Wang L
Genet Mol Res; 2015 Mar; 14(1):2099-103. PubMed ID: 25867356
[TBL] [Abstract][Full Text] [Related]
29. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment?
Beije N; Jager A; Sleijfer S
Cancer Treat Rev; 2015 Feb; 41(2):144-50. PubMed ID: 25542852
[TBL] [Abstract][Full Text] [Related]
31. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
32. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood immune markers in breast cancer: Differences in regulatory T cell abundance are related to clinical parameters.
Jørgensen N; Lænkholm AV; Sækmose SG; Hansen LB; Hviid TVF
Clin Immunol; 2021 Nov; 232():108847. PubMed ID: 34506945
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.
Pierga JY; Bidard FC; Mathiot C; Brain E; Delaloge S; Giachetti S; de Cremoux P; Salmon R; Vincent-Salomon A; Marty M
Clin Cancer Res; 2008 Nov; 14(21):7004-10. PubMed ID: 18980996
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
Barthélémy P; Heitz D; Mathelin C; Polesi H; Asmane I; Litique V; Rob L; Bergerat JP; Kurtz JE
Crit Rev Oncol Hematol; 2011 Aug; 79(2):196-204. PubMed ID: 20655243
[TBL] [Abstract][Full Text] [Related]
37. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
38. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Riethdorf S; Müller V; Zhang L; Rau T; Loibl S; Komor M; Roller M; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Eidtmann H; Untch M; von Minckwitz G; Pantel K
Clin Cancer Res; 2010 May; 16(9):2634-45. PubMed ID: 20406831
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection.
Daskalakis M; Mavroudis D; Sanidas E; Apostolaki S; Askoxylakis I; de Bree E; Georgoulias V; Melissas J
Eur J Surg Oncol; 2011 May; 37(5):404-10. PubMed ID: 21376504
[TBL] [Abstract][Full Text] [Related]
40. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Mavroudis D; Kouroussis C; Mavroudi C; Perraki M; Sivridis E; Georgoulias V
Int J Cancer; 2004 Feb; 108(4):620-7. PubMed ID: 14696130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
